The European Association for the Study of Obesity (EASO) published in Nature Medicine an algorithm for pharmacological treatment of obesity and its complications.[3] The algorithm is based on a framework that aligns the diagnosis, severity assessment and treatment of obesity with the standards of other chronic diseases and defines obesity as a chronic disease based on adiposity.[1][3] It provides physicians with practical guidance for tailoring treatment to the individual patient profile based on the analysis of randomized controlled trials.[3] EASO recommends pharmacotherapy for patients with BMI ≥ 25 kg/m² and the presence of obesity comorbidity, which is a lower threshold than the previous recommendation of BMI ≥ 27 kg/m².[1] Treatment involves a holistic approach beyond weight reduction, with an emphasis on complications, mental health, physical function, and quality of life.[3] The data used in the algorithm was available at the beginning of 2025 and will be updated.[3] The article clarifies the selection of evidence for this framework.[3]